The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Iakovleva Iu.A.

FGBU "Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva" MZ RF, Sankt-Peterburg

Yanaeva A.N.

Saint-Petersburg’s «Psychoneurological Boarding №7», St.-Petersburg, Russia

Spikina A.A.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Rukavitsyna E.L.

«UCB Pharma», Moscow, Russia

Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders

Authors:

Iakovleva Iu.A., Yanaeva A.N., Spikina A.A., Rukavitsyna E.L.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10‑2): 98‑104

DOI: 10.17116/jnevro201811810298

Read: 1072 times

Download PDF (RU)
Contact the author
Table of contents

LACOSAMIDE IN TREATMENT OF PATIENTS WITH FOCAL EPILEPSY AND COMORBID MENTAL DISORDERS
LACOSAMIDE IN TREATMENT OF PATIENTS WITH FOCAL EPILEPSY AND COMORBID MENTAL DISORDERS

To cite this article:

Iakovleva IuA, Yanaeva AN, Spikina AA, Rukavitsyna EL. Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10‑2):98‑104. (In Russ.)
https://doi.org/10.17116/jnevro201811810298

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
Nutritional care for patients with neurodegenerative diseases in the outpatient practice of a neurologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):76-83
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Pera­mpanel treatment in IQSEC2-associated epileptic ence­phalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):143-149
Possibilities of vibroacoustic therapy application in patients with chro­nic bronchopulmonary pathology. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(1):12-18
Adolescent suicide risk asse­ssment using the Suicide Risk Rapid Survey. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):86-93
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Review and reso­lution of the Council of Expe­rts on the topic «The role of the combination of unde­natured type II collagen UC-II, vita­min C, and trace elements in reco­vering and maintaining the function of the musculoskeletal system, and preservation of health of the joints». Russian Journal of Preventive Medi­cine. 2025;(4):102-110
Abstract:

In this article, the results of personal prospective observation of lacosamide (LCM) administration in 91 adults with epilepsy and comorbid mental disorders are presented. LCM was administered as a part of polytherapy for 80 patients at a dose of up to 400 mg/day and of monotherapy for 11 patients at a dose of up to 600 mg/day for up to 12 months. Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.

Keywords:

treatment of epilepsy
LCM
vimpat
comorbidity
dementia
suicide
mental disorders

Authors:

Iakovleva Iu.A.

FGBU "Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva" MZ RF, Sankt-Peterburg

Yanaeva A.N.

Saint-Petersburg’s «Psychoneurological Boarding №7», St.-Petersburg, Russia

Spikina A.A.

Severo-Zapadnyĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.I. Mechnikova, Sankt-Peterburg

Rukavitsyna E.L.

«UCB Pharma», Moscow, Russia

Close metadata

References:

  1. Gaitatzis A, Carroll K, Majeed A, Sander JW. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia. 2004;45(12):1613-1622. https://doi.org/10.1111/j.0013-9580.2004.17504.x
  2. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012;380:1180-1192. https://doi.org/10.1016/S0140-6736(12)61455-X
  3. Hamilton KT, Anderson CT, Dahodwala N, Lawler K, Hesdorffer D, French J, Pollard JR. Utilization of care among drug resistant epilepsy patients with symptoms of anxiety. Seizure — European Journal of Epilepsy. 2014;23(3):196-200. https://doi.org/10.1016/j.seizure.2013.11.012
  4. Avakyan GN, Blinov DV, Lebedeva AV, Burd SG, Avakyan GG. ILAE Classification of the epilepsies: the 2017 revision and update. Epilepsiya i paroksizmal’nye sostoyaniya. Epilepsy and Paroxysmal Conditions. 2017;9(1):6-25. (In Russ.) https://doi.org/10.17749/2077-8333.2017.9.1.006-025
  5. Josephson CB, Jett N. Psychiatric comorbidities in epilepsy. International Review of Psychiatry. 2017;29(5):409-424. https://doi.org/10.1080/09540261.2017.1302412
  6. Kraepelin E. Introduction to the psychiatric clinic. Per. Gilyarovsky V.A. 4 th ed., Pererab. M.—Petrograd: Gos. publishing house; 1923. (In Russ.)
  7. Boldirev AI. Mental features of patients with epilepsy. M.: Medicine; 2000. (In Russ.)
  8. Wiglusz MS, Cubała WJ, Gałuszko-Węgielnik M, Jakuszkowiak-Wojten K, Landowski J. Mood disorders in epilepsy — diagnostic and methodological considerations. Psychiatria Danubina. 2012;24(1):44-50.
  9. Dokukina TV, Makhrov MV, Gaydukevich IV, Gilep AA, Golubeva TS, Khlebokazov FP, Misyuk NN, Korolevich PP. Opportunities to Optimize Antiepileptic Therapy with Use of Pharmacogenetic Biomarkers. Epilepsy and Paroxysmal Conditions. 2015;4:22-28 (In Russ.) http://www.epilepsia.su/jour/article/view/10
  10. Mula M. Investigating psychotropic properties of antiepileptic drugs. Expert Rev Neurother. 2013;13(6):639-646. https://doi.org/10.1586/ern.13.57
  11. Brodie MJ, Besag FMC, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, Steinhoff BJ. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016;68:563-602. https://doi.org/10.1124/pr.115.012021
  12. Park SP, Kwon SH. Cognitive Effects of Antiepileptic Drugs. J Clin Neurol. 2008;4:99-106. https://doi.org/10.3988/jcn.2008.4.3.99
  13. Witt JA, Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opinion on Pharmacotherapy. 2017;18(6):551-554. https://doi.org/10.1080/14656566.2017.1309025
  14. Rudakova IG, Vlasov PN, Lipatova LV, Voronkova KV. Lacosamide (vimpat). Prospects for clinical application. Journal of Neurology and Psychiatry im. S.S. Korsakov. 2017;117(9):147-152 (In Russ.) https://doi.org/10.17116/jnevro201711791147-152
  15. Lebedeva AV, Burd SG, Belyaev OV, Vlasov PN, Dorofeeva MYu, Ismailov AM, Kissin MYa, Kovaleva IYu, Koroleva NYu, Lipatova LV, Mukhin KYu, Solomatin YuV, Chervyakov AV, Shikhkerimov RG, Pylaeva OA, Freidkova NV. Russian experience of lacosamide (vimpat) usage in treatment of uncontrolled focal epilepsy. Journal of Neurology and Psychiatry im. S.S. Korsakov. 2016;116(9-2):74-81. (In Russ.) https://doi.org/10.17116/jnevro20161169274-81
  16. Helmstaedter C, Witt JA. The longer-term cognitive effects of ajunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepcy & Behavior. 2013;26:182-187. https://doi.org/10.1016/j.yebeh.2012.11.052
  17. Ijff DM, van Veenendaal TM, Majoie HJ, de Louw AJ, Jansen JF, Aldenkamp AP. Cognitive effects of lacosamide as adjunctive therapy in refractory epilepsy. Acta Neurol Scand. 2015;13:347-354. https://doi.org/10.1111/ane.12372
  18. Gurvich IN, Rusakova MM, Malakhov KYu, Bocharov AV, Antonova NA. Scale is a comprehensive assessment of the mental state. A methodological guide. SPb. 2003. (In Russ.)
  19. Witt J-A, Elger CE, Helmstaedter C. Which drug-induced side effects would be tolerated in the prospect of seizure control? Epilepsy Behav. 2013;29(1):141-143. https://doi.org/10.1016/j.yebeh.2013.07.013
  20. Moseley BD, Cole D, Iwuora O, Strawn JR, Privitera M. The effects of lacosamide on depression and anxiety in patients with epilepsy. Epilepsy Research. 2015;110:115-118. https://doi.org/10.1016/j.eplepsyres.2014.1012.1007
  21. Karlov VA, Guekht AB, Guzeva VI, Lipatova LV, Bazilevich SN, Mkrtchyan VR, Vlasov PN, Zhidkova IA, Mukhin KYu, Petrukhin AS, Lebedeva AV. Algorithms of mono- and polytherapy in clinical epileptology. Part 1. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(6):109-114. (In Russ.) https://doi.org/10.17116/jnevro201611661109-114
  22. Karlov VA, Guekht AB, Guzeva VI, Lipatova LV, Bazilevich SN, Mkrtchyan VR, Vlasov PN, Zhidkova IA, Mukhin KYu, Petrukhin AS, Lebedeva AV. Algorithms of mono- and polytherapy in clinical epileptology. Part 2. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2016;116(7):120-129. https://doi.org/10.17116/jnevro201611671120-129 (In Russ.)
  23. Moutal A, François-Moutal L, Perez-Miller1 S, Cottier1 K, Chew LA, Ki YS, Dai J, Park KD, Khanna M, Khanna R. 1,2 (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Mol Neurobiol. 2016;53:1959-1976. https://doi.org/10.1007/s12035-015-9141-2
  24. Pohlmann-Eden B, Eden MA. Dementia and epilepsy. In Trimble MR, Shmitz B, editors. The Neuropsychiatry of Epilepsy. New York: Cambridge Yniversyty Press; 2011. https://doi.org/10.1017/cbo9780511977145.006
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.